We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This study was designed to identify neutralizing antibodies against SARS-CoV-2.
Passive transfer of either COV2-2196 or COV2-2130 alone or in combination protected mice from weight loss and reduced viral burden and lung inflammation. Passive transfer of ACE2-blocking antibodies protected rhesus macaques from SARS-CoV-2 infection.
– Neil Majithia, MD
This abstract is available on the publisher's site.
The COVID-19 pandemic is a major threat to global health1 for which there are limited medical countermeasures2,3. Moreover, we currently lack a thorough understanding of mechanisms of humoral immunity4. From a larger panel of human monoclonal antibodies (mAbs) targeting the spike (S) glycoprotein5, we identified several that exhibited potent neutralizing activity and fully blocked the receptor-binding domain of S (SRBD) from interacting with human ACE2 (hACE2). Competition-binding, structural, and functional studies allowed clustering of the mAbs into classes recognizing distinct epitopes on the SRBD as well as distinct conformational states of the S trimer. Potent neutralizing mAbs recognizing non-overlapping sites, COV2-2196 and COV2-2130, bound simultaneously to S and synergistically neutralized authentic SARS-CoV-2 virus. In two mouse models of SARS-CoV-2 infection, passive transfer of either COV2-2196 or COV2-2130 alone or a combination of both mAbs protected mice from weight loss and reduced viral burden and inflammation in the lung. In addition, passive transfer of each of two of the most potently ACE2 blocking mAbs (COV2-2196 or COV2-2381) as monotherapy protected rhesus macaques from SARS-CoV-2 infection. These results identify protective epitopes on SRBD and provide a structure-based framework for rational vaccine design and the selection of robust immunotherapeutics.
Potently Neutralizing and Protective Human Antibodies Against SARS-CoV-2
Nature 2020 Jul 15;[EPub Ahead of Print], SJ Zost, P Gilchuk, JB Case, E Binshtein, RE Chen, JP Nkolola, A Schäfer, JX Reidy, A Trivette, RS Nargi, RE Sutton, N Suryadevara, DR Martinez, LE Williamson, EC Chen, T Jones, S Day, L Myers, AO Hassan, NM Kafai, ES Winkler, JM Fox, S Shrihari, BK Mueller, J Meiler, A Chandrashekar, NB Mercado, JJ Steinhardt, K Ren, YM Loo, NL Kallewaard, BT McCune, SP Keeler, MJ Holtzman, DH Barouch, LE Gralinski, RS Baric, LB Thackray, MS Diamond, RH Carnahan, JE Crowe